Edition:
United Kingdom

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

19.91USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$19.91
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
365,701
52-wk High
$27.07
52-wk Low
$8.36

Latest Key Developments (Source: Significant Developments)

FDA Grants Breakthrough Therapy Designation To Omeros' Masp-2 Inhibitor Oms721
Thursday, 26 Apr 2018 

April 26 (Reuters) - Omeros Corp ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO OMEROS’ MASP-2 INHIBITOR OMS721 FOR THE TREATMENT OF HIGH-RISK HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY.DISCUSSIONS ONGOING WITH FDA AND EUROPEAN REGULATORS FOR EXPEDITED APPROVAL OF OMS721.  Full Article

Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Omeros Corp ::OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY.OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY.OMEROS CORP - ‍INITIATES OMS721 PHASE 3 PROGRAM IN HCT-TMA​.OMEROS CORP - ‍ PATIENT ENROLLMENT FOR ITS PHASE 3 CLINICAL TRIAL EVALUATING OMS721 IN PATIENTS WITH IGA NEPHROPATHY IS EXPECTED TO BEGIN EARLY IN FEB.  Full Article

Omeros Corporation Announces Fda Approval Of Omidria For Use In Pediatric Patients
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Omeros Corp ::OMEROS CORPORATION ANNOUNCES FDA APPROVAL OF OMIDRIA® FOR USE IN PEDIATRIC PATIENTS.FDA APPROVED SNDA FOR OMIDRIA UNDER PRIORITY REVIEW.  Full Article

Omeros Corp reports Q3 loss per share $0.16
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Omeros Corp :Omeros Corporation reports third quarter 2017 financial results.Q3 loss per share $0.16.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.Q3 revenue $21.7 million versus i/b/e/s view $17.9 million.Omeros Corp - ‍as of sept 30, 2017, co had $86.8 million of cash & cash equivalents available for operations & $5.8 million in restricted cash​.  Full Article

OMEROS REPORTS ADDITIONAL POSITIVE DATA FOR OMS721
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Omeros Corp ::OMEROS REPORTS ADDITIONAL AND CONSISTENTLY POSITIVE DATA FOR OMS721 IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY.‍OMS721 HAS BEEN WELL TOLERATED AND NO SAFETY CONCERNS HAVE BEEN IDENTIFIED​.3 OF 4 PATIENTS FOR WHOM OMS721 TREATMENT WAS DISCONTINUED EARLY EXPERIENCED DETERIORATION OF THEIR CONDITIONS AND SUBSEQUENTLY DIED​.‍PREPARING TO INITIATE OMS721 PHASE 3 CLINICAL TRIAL, PURSUING FDA'S BREAKTHROUGH THERAPY DESIGNATION, EUROPEAN MEDICINES AGENCY'S PRIME STATUS​.  Full Article

Omeros Corp amends term loan agreement
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Omeros Corp :On Oct 11, co entered amendment no. 1 to loan agreement, which amended term loan agreement, dated October 26, 2016​.Pursuant to amendment, co to access second, third tranches of debt financing under loan agreement for up to $25 million and $20 million.  Full Article

Omeros announces pricing of public offering of common stock
Thursday, 11 Aug 2016 

Omeros Corp : Omeros announces pricing of public offering of common stock .Pricing of a $40 million underwritten public offering of its common stock at a price to public of $11.50 per share.  Full Article

Omeros announces public offering of common stock
Wednesday, 10 Aug 2016 

Omeros Corp : Omeros announces public offering of common stock . Intends to use net proceeds for funding research and development expenses for its clinical OMS721 program and clinical trials .Says announced an agreement to sell $40 million of shares of its common stock to Cantor Fitzgerald & Co..  Full Article

Omeros confirms late-stage development plan for OMS721 with EMA
Thursday, 28 Jul 2016 

Omeros Corp : Omeros corporation confirms oms721 phase 3 development plan with european medicines agency . Initiation of enrollment in ahus phase 3 clinical trial is planned for late this year . Omeros plans to commercialize oms721 initially for administration as a subcutaneous injection .One single-arm, open-label phase 3 pivotal trial planned to support approval in both europe and u.s..  Full Article

BRIEF-Omeros Says Entered Into Settlement Agreement And Consent Judgment With Lupin Ltd and unit Lupin Pharmaceuticals - SEC Filing

* OMEROS SAYS ENTERED INTO SETTLEMENT AGREEMENT AND CONSENT JUDGMENT WITH LUPIN LTD, SUBSIDIARY LUPIN PHARMACEUTICALS - SEC FILING